بدائل البحث:
larger decrease » marked decrease (توسيع البحث)
linear decrease » linear increase (توسيع البحث)
teer decrease » mean decrease (توسيع البحث), greater decrease (توسيع البحث)
we decrease » _ decrease (توسيع البحث), a decrease (توسيع البحث), nn decrease (توسيع البحث)
larger decrease » marked decrease (توسيع البحث)
linear decrease » linear increase (توسيع البحث)
teer decrease » mean decrease (توسيع البحث), greater decrease (توسيع البحث)
we decrease » _ decrease (توسيع البحث), a decrease (توسيع البحث), nn decrease (توسيع البحث)
-
481
-
482
-
483
-
484
Comparison of adhesiveness ranges for different food categories under IDDSI levels.
منشور في 2025الموضوعات: -
485
-
486
-
487
-
488
Statistical analysis of adhesiveness, hardness, and cohesiveness across IDDSI levels.
منشور في 2025الموضوعات: -
489
Comparison of hardness ranges for different food categories under IDDSI levels.
منشور في 2025الموضوعات: -
490
-
491
-
492
-
493
-
494
-
495
-
496
Data from: <b>Selection and genetic variation in plasticity drive age-related decreases in among-individual behavioural correlations</b>
منشور في 2025"…Our findings indicate that the magnitudes of both the positive among-individual and genetic correlations were maintained across nymph and young adult stages, but significantly decreased with age during adulthood. This decrease was due to both selection and genetic variation in age-related behavioural plasticity. …"
-
497
-
498
-
499
Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf
منشور في 2025"…Ruxolitinib, a JAK/STAT inhibitor, has been shown to improve cutaneous manifestations of SLE. We hypothesize that the addition of ruxolitinib to UCB-Tregs may improve SLE outcomes.…"
-
500
Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf
منشور في 2025"…Ruxolitinib, a JAK/STAT inhibitor, has been shown to improve cutaneous manifestations of SLE. We hypothesize that the addition of ruxolitinib to UCB-Tregs may improve SLE outcomes.…"